Chronic Obstructive Pulmonary Disease (COPD) Market Size, Growth Drivers And Forecast 2032 At A Thriving CAGR Of 4.82%
Chronic obstructive pulmonary disease (COPD) market Insights: Rising prevalence of COPD due to aging and smoking.
Amarillo Globe-News on MSN8h
What are Zephyr Valves? Groundbreaking COPD treatment brings hope to Panhandle patients
After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...
Commonly prescribed medications can increase fall risk and related injuries in people with COPD
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
News Medical on MSN5d
The impact of fall-risk medications on injuries in COPD patients
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
Crain's New York7d
Midtown-based startup raises $12M in growing market for lung disease treatment
A Midtown-based medical device startup is carving a niche in the growing field of treatments to address chronic lung disease.
manilatimes12d
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary ...
EurekAlert!6d
Commonly prescribed medications increase fall risk and related injuries in people with COPD
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study.
Expanded research on COPD and metabolic syndrome would advance patient-centered care, expert argues
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
2minutemedicine.com4h
Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...
Pharmaceutical Technology20d
TRN-157 by Theron Pharmaceuticals for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
TRN-157 is under clinical development by Theron Pharmaceuticals and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).